These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Dencker SJ J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744 [TBL] [Abstract][Full Text] [Related]
3. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry]. Stip E Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180 [No Abstract] [Full Text] [Related]
4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them]. Canceil O; Limosin F; Passerieux C Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178 [No Abstract] [Full Text] [Related]
5. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Patel MX; De Zoysa N; Bernadt M; David A J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with neuroleptics in psychiatry. Shepherd M; Watt DC Curr Dev Psychopharmacol; 1977; 4():215-47. PubMed ID: 23248 [No Abstract] [Full Text] [Related]
7. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics]. Costentin J Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181 [No Abstract] [Full Text] [Related]
8. [Use of slow-release injections to administer antipsychotic drugs]. Høiseth G; Bentsen H Tidsskr Nor Laegeforen; 2012 Feb; 132(3):301-3. PubMed ID: 22314741 [TBL] [Abstract][Full Text] [Related]
9. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP]. Buis C; Gourion D; Vaiva G Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185 [No Abstract] [Full Text] [Related]
10. The underutilization of depot neuroleptic therapy. Balon R J Clin Psychiatry; 1994 Jan; 55(1):39. PubMed ID: 7904995 [No Abstract] [Full Text] [Related]
11. Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430 [TBL] [Abstract][Full Text] [Related]
12. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)]. Chéreau I; Gorwood P; Mouchabac S Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186 [No Abstract] [Full Text] [Related]
13. Psychiatric nurses' attitudes to antipsychotic depots in Hong Kong and comparison with London. Patel MX; Yeung FK; Haddad PM; David AS J Psychiatr Ment Health Nurs; 2008 Nov; 15(9):758-66. PubMed ID: 18844802 [TBL] [Abstract][Full Text] [Related]
14. Is depot medication safe in the setting of myopathy? Price JR; Bastiampillai T; Dhillon RS Aust N Z J Psychiatry; 2009 Aug; 43(8):781-3. PubMed ID: 19629801 [No Abstract] [Full Text] [Related]